DICE Therapeutics, Inc.
DICEDelisted Aug 9, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645569
DICE Therapeutics, Inc. was delisted on Aug 9, 2023; its insiders filed their last Form 4 on Aug 9, 2023; 160 institutions reported holding it in 13F filings for Q2 2023, worth $2.12B in total; Fairfax Financial was the only superinvestor holding it.
Q1 2022 vs. Q4 2021
How the institutions holding DICE Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Of which not filed for Q1 2022 | Q1 2022 | Change |
|---|---|---|---|---|
| Holders | 69 | 1 | 76 | +8 |
| Shares | 31.7M | 185.2K | 33.4M | +1.86M (+5.9%) |
| Value | $799.4M | $4.69M | $637.5M | −$157.2M (−19.8%) |
1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held DICE Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Point72 Asset Management, L.P. | 398,000 | $7.61M | 0.03% |
| Samsara BioCapital, LLC | 228,466 | $4.37M | 1.11% |
| First Manhattan Co | 180,122 | $3.44M | 0.01% |
| DAFNA Capital Management LLC | 94,000 | $1.80M | 0.47% |
| HighVista Strategies LLC | 48,960 | $937.0K | 0.60% |
| Manufacturers Life Insurance Company, The | 47,588 | $917.4K | 0.00% |
| Acuta Capital Partners, LLC | 37,500 | $717.0K | 0.34% |
| State of Wisconsin Investment Board | 18,600 | $356.0K | 0.00% |
| Trexquant Investment LP | 16,084 | $308.0K | 0.01% |
| Prelude Capital Management, LLC | 14,698 | $281.0K | 0.01% |
| Cutler Group LP | 14,600 | $279.0K | 0.03% |
| Goldman Sachs Group Inc | 13,035 | $249.0K | 0.00% |
| Parkwood LLC | 12,417 | $238.0K | 0.04% |
| Simplex Trading, LLC | 10,843 | $207.0K | 0.01% |
| Barclays PLC | 2,861 | $55.0K | 0.00% |
| Amalgamated Bank | 2,029 | $39.0K | 0.00% |
| Prospera Financial Services Inc | 2,052 | $39.0K | 0.00% |
| Amalgamated Financial Corp. | 2,029 | $39.0K | 0.00% |
Sold out (10)
Institutions that held DICE Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Suvretta Capital Management, LLC | 410,000 | $10.4M |
| Polar Asset Management Partners Inc. | 75,014 | $1.90M |
| HealthCor Management, L.P. | 74,774 | $1.89M |
| Marshall Wace, LLP | 42,500 | $1.07M |
| Atom Investors LP | 39,100 | $990.0K |
| Nan Fung Group Holdings Ltd | 19,700 | $499.0K |
| Jump Financial, LLC | 15,500 | $393.0K |
| LMR Partners LLP | 15,387 | $389.0K |
| Renaissance Technologies LLC | 8,400 | $213.0K |
| M&T Bank Corp | 8,280 | $210.0K |
Not filed for Q1 2022 yet (1)
Institutions that held DICE Therapeutics, Inc. at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Asymmetry Capital Management, L.P. | 185,201 | $4.69M |